Hong Kong-based Regencell has seen its stock explode higher this year on essentially no news.

The developer of traditional Chinese herbal treatments for childhood ADHD and autism is up roughly 59,000% year to date.

Regencell Bioscience, a Hong Kong-based biotech startup with no reported revenue, has gained more than 59,000% in 2025.

Huadong Medicine Co., Ltd. engages in the production and sale of antibiotics, proprietary Chinese medicine, chemical synthetic medicine, and genetic engineering drugs. It involves in wholesale ...

Consolidated profit attributable to equity shareholders grew by 51.2% to HK$197.3 million - The Board recommends a final dividend of HK11.5 cents per share - Flagship proprietary brands Ho Chai Kung, ...

Liu Xinmin said, “this is China’s first proprietary Chinese medicine to complete clinical trials guided by drug registration abroad, and it is also the first proprietary Chinese medicine to be ...